CYP3A4 and non-small cell lung carcinoma: This enhancement becomes critical when considering co-administration with tyrosine kinase inhibitors (TKIs), which are widely utilized in the targeted treatment of various malignancies, such as leukemia, non-small cell lung cancer (NSLC), and certain breast cancers, due to their primary metabolism via CYP3A4 [13].